# Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

> **NCT05790447** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Soochow University** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Refractory Tumor

## Interventions

- **DRUG:** Thymalfasin
- **RADIATION:** Radiotherapy
- **DRUG:** PD-1/PD-L1 inhibitor
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT05790447
- **Lead sponsor:** Second Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05790447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05790447, "Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05790447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*